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Dear Friends and Colleagues,
It is our pleasure to share with you the Children’s
Mercy Kansas City Fiscal Year 2014 Annual
Research Report. Our researchers, health care
professionals and our nearly 7,000 employees
across our academic pediatric medical system
continue to embrace the truth that scientific
discovery and knowledge creation are central to
our core mission of improving the health and well
being of our patients and families by delivering the
very best pediatric care. And Children’s Mercy is
uniquely positioned to advance pediatric medicine
to the next level because of the long-standing and
devoted support of the community.
As reflected by the information contained within
this report, this past year was one of continued
growth of our academic research enterprise at
Children’s Mercy. This was driven by initiation of a
visionary Research Strategic Plan, a fully integrated
component of the hospital’s new strategic plan
which demonstrates that biomedical research
remains as a mission-centric priority for Children’s
Mercy.

Annual reports don’t typically make for great
reading material. This year, we’ve chosen to provide
a shorter Annual Research Report, featuring just
two of our key initiatives. First is the development of
four research areas of emphasis, a strategy which
we will use to provide a more nimble structure to
our research enterprise and to focus our continued
institutional investment in research.
Second, in collaboration with the University of
Kansas Medical Center, Children’s Mercy took
decisive steps toward creating a single Department
of Pediatrics which is intended to serve the clinical,
educational and research needs of children in our
region. This strategic partnership will dramatically
improve our ability to link basic, translational and
clinical research in pediatrics and, thereby, leverage
the success of our two institutions in attracting and
retaining the best and brightest minds in pediatric
medical research to Kansas City.

We urge you to visit the new Children’s Mercy
research website (childrensmercy.org/research) to
learn more about our research enterprise and the
accomplishments of our dedicated scientists and
clinicians who make this work possible.
We hope that you will take a few moments to
read through this report, reflect on it, and most
importantly, share in the celebration of success
as we work together to continue the evolution of
Children’s Mercy as a world-class institution for
pediatric research. As our research enterprise
expands, we will ensure that the patients we
are privileged to care for and those beyond the
boundaries of our institution will benefit from the
very best that new discoveries and knowledge can
provide. Thank you for embarking with us on this
remarkable journey that will advance pediatric
health care across the globe.

During FY2014, Children’s Mercy Kansas City
embarked on a new, ambitious Research
Strategic Plan. In addition to building
institutional infrastructure to support
research, four strategic research areas of
emphasis were defined to provide thematic
focal points for continued development of the
Children’s Mercy Research Enterprise.
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We hope you feel as
proud as we are grateful.
Your contributions helped
make possible the
following accomplishments
within each of our
research pillars.

Clinical Pharmacology and
Therapeutic Innovation

J. Steven Leeder, PharmD, PhD
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The Division of Clinical Pharmacology and
national trial of hydroxyurea for sickle cell disease as
Therapeutic Innovation, under the direction of J.
part of the NICHD Pediatric Trials Network.
Steven Leeder, PharmD, PhD, is driven by the concept
of “integrated research” in which clinical questions
In addition, the Experimental Therapeutics Program
related to variability in drug response are first
is actively pursuing pediatric sarcoma drug
identified at the patient level. These patient-derived
discovery and re-formulation. The Clinical Toxicology
problems are used to guide the development
program, a member of the national Network of
of a specific project or program, which involves
Pediatric Environmental Health Specialized Units,
identification
was awarded an
and application
Environmental
Dr. Leeder holds the Marion Merrell Dow/Missouri Endowed Chair
of the most
in Pediatric Clinical Pharmacology. Established by forward-thinking Education Grant by
appropriate
the Environmental
donors, endowed chairs provide ongoing financial support for
research tools
Protection Agency
research and education and are of strategic importance to elevate
to answer the
(EPA).
the hospital’s academic profile and stature as a national leader in
clinical question. clinical care. The Missouri Endowed Chairs stand as an important
example of the success made possible through match challenge
Finally, through
programs that engage and inspire other philanthropists and
Participation
strategic research
attract
the
best
and
brightest
physician-scientists
to
Kansas
City.
of the CPTI
collaborations with
Experimental
the Institute for
Therapeutics
Advancing Medical
Program in Pediatric Cancer in four national
Innovation, the University of Kansas Cancer Center,
networks (POETIC, NMTRC, TACL and COG) enabled
and Orbis Biosciences, CPTI faculty are working to
patients from Missouri, Kansas and in neighboring
develop new, innovative formulations of critical drugs
states to have access to more than 30 early phase
that are suitable for the treatment of childhood
clinical trials in 2013. With active support from the
cancers and other pediatric diseases.
National Institutes of Health, the program led a

Genomic Medicine
Led by Stephen Kingsmore, MB, BAO, ChB, DSc, FRCPath, the Children’s Mercy Center for Pediatric Genomic
Medicine is the only such program housed in a free-standing children’s medical center in the United States.
During the past year, Dr. Kingsmore and his colleagues successfully launched a novel genomic analysis
technique (TaGSCAN – Targeted Gene Sequencing and Custom Analysis) that provides rapid and costeffective DNA-based diagnosis of hundreds of hereditary diseases.
Coupled with STAT-Seq, another new gene-based diagnostic
test developed by the Center for Pediatric Genomic Medicine,
Dr. Kingsmore and his collaborators at Children’s Mercy were
able to accurately determine the etiology in approximately
one-third of neonates and children with previously undiagnosed
neurodevelopmental conditions. This work is supported by grants
from the Marion Merrell Dow Donor Advised Fund, the Claire
Giannini Fund, a $1 million grant from the William T. Kemper
Foundation, a $5 million grant from the Eunice Kennedy Shriver
National Institute of Child Health and Human Development and
the National Human Genome Research Institute. Dr. Kingsmore
and his team were awarded a five-year, $6 million grant from
the National Institutes of Health to further develop STAT-Seq and
determine its benefits in 500 babies from the Children’s Mercy
Hospital Neonatal Intensive Care Unit.

On May 22, 2014, friends, family,
colleagues, and donors gathered
to celebrate Dr. Kingsmore and the
formal investiture of the Dee Lyons/
Missouri Endowed Chair in Pediatric
Genomic Medicine made possible by
the generous support and leadership
of Fred and Dee Lyons. “Children’s
Mercy is starting to become a
national leader in pediatric genomic
medicine,” said Dr. Kingsmore.
“This honor allows our team to
develop further research initiatives
and, ultimately, improve outcomes
and quality of life of children with
pediatric genetic diseases.”

Stephen Kingsmore, MB,
BAO, ChB, DSc, FRCPath

Health Services and Outcomes
FY14 saw the establishment of the Children’s Mercy Center for Health Services and Outcomes Research with
the recruitment of Kathy Goggin, PhD, the Ernest L. Glasscock Endowed Chair in Pediatric Education and
Research and Director of this new center.
The center has created multidisciplinary teams
in high-impact areas (e.g., pediatric obesity,
genomic medicine) to provide the structure and
focus necessary to design and conduct research
to determine the impact of translational research
conducted by investigators at Children’s Mercy.
Additionally, the center has developed new, and
bolstered existing relationships with faith and
community-based organizations in Kansas City
for the purpose of fostering broad engagement in
the research process and to ensure that research
focused on improving care in the community is
having the desired impact to improve the lives of
children and those that care for them.

Kathy Goggin, PhD
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We also had the pleasure of celebrating Dr.
Goggin and the formal investiture of the Ernest L.
Glasscock Endowed Chair in Pediatric Education
and Research made possible by the generous
support of Dr. Ernest Glasscock, who was a
long-time friend of Children’s Mercy. “Children’s
Mercy is focused on discovering new methods
for enhancing the patient-care experience and
promoting the best possible treatment outcomes,”
Dr. Goggin said. “This (gift) will allow us to gather
further knowledge by regularly measuring our
performance and to continue to support our
commitment to maintaining a high standard of
care for all patients, regardless of racial, ethnic or
economic background.”

Finally, this new center is developing important strategic research collaborations with institutions in the
Kansas City metropolitan area (e.g., Saint Luke’s Hospital Mid-America Heart Institute, University of MissouriKansas City and University of Kansas), throughout the United States (e.g., Boston Children’s Hospital,
University of California San Diego, University of Washington and Yale University) and across the globe (e.g.,
University of Paris Nanterre, Kenya Medical Research Institute and University of Capetown).

Innovations in Health Care Delivery
With direction and leadership provided by David World Health Organization, Dr. Abdel-Rahman
H. Westbrook, Senior Vice President for Strategy has validated the accuracy of the Mercy TAPE in
and Innovation, Children’s Mercy has initiated
pediatric patients on four continents.
a program designed to develop information,
resources and products that have the potential
In December 2013, Laura Fitzmaurice, MD,
to improve the scope and quality of health care
Professor of Pediatrics and Children’s Mercy
delivery to infants, children and adolescents in
Chief Medical Information Officer, received
our region and
notification the Patientbeyond.
Centered Outcomes
Research at Children’s Mercy is taking many
Research Institute
forms, from innovative tests that can diagnose
The past
(PCORI) had awarded
genetic illnesses more quickly than ever before,
to evidence-based delivery-of-care models that
year saw the
almost $7 million to
increase
patient
satisfaction
and
outcomes.
development
support the Greater
Children’s Mercy supporters touch every clinical
of two highly
Plains Collaborative, led
study,
every
published
paper
and
every
child
significant
by Russ Waitman, PhD,
whose
life
is
changed
as
a
result
of
that
research.
innovations.
at Kansas University
Susan AbdelMedical Center. The
Rahman, PharmD, a Professor of Pediatrics
Collaborative represents a new network of
and member of the Children’s Mercy Division
10 leading medical centers in seven states
of Pediatric Pharmacology and Therapeutic
committed to a shared vision of improving
Innovation, received a U.S. patent for the
health care delivery through the use of medical
Mercy TAPE, a device that costs pennies to
informatics to drive the adoption of evidencemanufacture and can reliably estimate body
based practices. Dr. Fitzmaurice will lead this
weight in any infant, child or adolescent. With
initiative at Children’s Mercy, the only children’s
support from the National Institutes of Health,
hospital included in the Greater Plains
the Food and Drug Administration and the
Collaborative.

Susan Abdel-Rahman, PharmD

Awards
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FELLOWSHIP AWARD
Ryan Funk, PharmD, PhD
“Methotrexate Activity and Disposition in Synoviocytes
Isolated from Patients with Juvenile Idiopathic
Arthritis”
Sandhya Ramlogan, MBChB
“Validation of Echocardiographic Measurements of
Ovine Ventricular Function and Volume in the IntraOperative Milieu”
Jamie Rosterman, DO
“Randomized Crossover of Neurally Adjusted
Ventilatory Assist in Infants”
Valentina Shakhnovich, MD
“PXR expression in Small Bowel Tissue of Pediatric
Patients with CD”
Jonathan Wagner, DO
“Pharmacokinetics of Pravastatin and Simvastatin
Pediatric Dyslipidemia Patients; Clinical Impact of
Genetic Variation in Statin Disposition”

KATHARINE B. RICHARDSON AWARD
R. Scott Duncan, PhD
“Regulation of Toll-Like Receptor Signaling During
CMV Exposure of Astrocytes”

MARION MERRELL DOW CLINICAL
SCHOLARS AWARD
Jennifer Goldman, MD
“Variation of Bioactivation and Detoxification of
Trimethoprim in Children”
Craig Freisen, MD
“The Effect of Obesity on the Pharmacokinetics of
Pantoprazole in Children and Adolescents”

KREAMER RESEARCH EXCELLENCE AWARD
Jason Newland, MD
“Implementation of Antimicrobial Stewardship
Interventions in Children’s Hospitals using
Benchmarking”

RESEARCH DAYS AWARD
•

Sunena Argo, MD (1st Place)
“The Use of Lymphocyte Transformation for the
Diagnosis of Delayed Hypersensitivity Drug
Reactions to Trimethoprim/Sulfamethoxazole”

PAUL HENSON ENDOWMENT CLINICAL
SCHOLAR AWARD
Christina Ciaccio, MD
“The Impact of Dietary Fatty Acids on the
Development of Food Sensitization”

YOUNG INVESTIGATOR AWARDS IN
CLINICAL/TRANSLATIONAL RESEARCH
Neil Mardis, DO
“Cartilage Damage Determined by 3Tesla MRI
Analysis in a Pediatric Population with Acute ACL
Injuries”
Stephani Stancil, MSN, APRN
“Evaluating the Effects of Nicotine and Ethinyl Estradiol
on the Metabolism of Metronidazole”

Category: PYG 4 and above (Fellow)

Tara Federly, MD (2nd Place)
“Food Specific IgE Levels in Children Should be
Intrepreted in Context of Total IgE”

•

Category: PYG 1-3 (1-4 for Med/Peds)
(Resident)
Jill Hanson, MD (1st Place)
“Ambulatory Exhaled Nitric Oxide Measurement
in Children 4-7 Years of Age”
Voytek Slowik, MD (2nd Place)
“Thyroid Cancer Complicating Familial
Adenomatous Polyposis: Mutation Spectrum of
At-Risk Individuals”

Philanthropy and Research
Philanthropy is in our DNA and will be the building
block of our future.
Our dream is to be the place where families across
the globe come when they need access to the most
innovative diagnostic techniques and treatments
in the world, and where local families receive ever
more individualized treatment right in their own
backyard. Research is the key to making this dream
a reality.
Sustaining research of this caliber is truly a
collaborative effort, including financial support from
the hospital, funding from public sources, both state
and national, and through the generous support
of donors. With your support and that of other
community partners, we have continued to elevate
our institution, advance the quality of our service and
improve the capabilities of our people.
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The strategic initiatives outlined here provide the
framework and focus for our existing vision – to be
a national and international leader for advancing
pediatric health and delivering optimal health
outcomes through innovation. Philanthropic
support will sustain our progress while driving the
possibilities of tomorrow. Philanthropic support
allows us to compete for and retain top talent, invest
in state-of-the-art equipment and technology and
build and create the research programs that lead
to more efficient and more clinically effective health
care, all while preserving the quality of care for
which we are widely recognized.
Thank you for all you do to transform the lives of
children!

Strategic Academic Initiatives
Under the leadership of Michael Artman, MD, and Steven Stites, MD,
Children’s Mercy and the University of Kansas Hospital, the University of
Kansas Medical Center and The University of Kansas Physicians are working
to develop a single, integrated pediatric program. The new program will
allow our institutions to further enhance clinical care for children, advance
pediatric academic development, expand our pediatric research initiatives,
and enhance our advocacy activities on behalf of children in our region. This
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activity was enhanced by the development of the Children’s Mercy – University
of Kansas School of Medicine Child Discovery Forum led by Gregory Kearns,
PharmD, PhD and Ann Davis, PhD, MPH, ABPP. This forum brings together
pediatric researchers from Children’s Mercy, the University of Kansas, University
of Missouri-Kansas City and the Kansas City University of Medicine and
Biosciences to discuss critical topics in pediatric medicine such as medication
adherence, obesity, drug development and genomic medicine.

Research Expenditures FY 2013 to 2014
FEDERAL
INDUSTRY
FOUNDATION AND COMMUNITY SUPPORT
OTHER REVENUE
TOTAL EXTERNALLY FUNDED RESEARCH
CMH FUNDED RESEARCH
TOTAL CMH RESEARCH

FY 13
$6,642,439
$1,474,109
$2,317,983
$0

FY 14
$6,743,379
$2,412,877
$3,371,254
$235,457

$10,434,531
$12,478,535

$12,762,968
$12,276,698

$22,913,066

$25,039,666

Research Development and
Clinical Investigation
2401 Gillham Road
Kansas City, MO 64108
(816) 701-1349

Visit our website at childrensmercy.org/research
for a more in-depth look at our research pillars.
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